PL2026796T3 - Zastosowanie inhibitora wazopeptydazy do leczenia tętniczego nadciśnienia płucnego - Google Patents

Zastosowanie inhibitora wazopeptydazy do leczenia tętniczego nadciśnienia płucnego

Info

Publication number
PL2026796T3
PL2026796T3 PL07788875T PL07788875T PL2026796T3 PL 2026796 T3 PL2026796 T3 PL 2026796T3 PL 07788875 T PL07788875 T PL 07788875T PL 07788875 T PL07788875 T PL 07788875T PL 2026796 T3 PL2026796 T3 PL 2026796T3
Authority
PL
Poland
Prior art keywords
treatment
arterial hypertension
pulmonary arterial
vasopeptidase inhibitor
vasopeptidase
Prior art date
Application number
PL07788875T
Other languages
English (en)
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Original Assignee
Bioprojet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet filed Critical Bioprojet
Publication of PL2026796T3 publication Critical patent/PL2026796T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07788875T 2006-06-13 2007-06-12 Zastosowanie inhibitora wazopeptydazy do leczenia tętniczego nadciśnienia płucnego PL2026796T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0605250A FR2902009B1 (fr) 2006-06-13 2006-06-13 Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire

Publications (1)

Publication Number Publication Date
PL2026796T3 true PL2026796T3 (pl) 2017-03-31

Family

ID=37603265

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07788875T PL2026796T3 (pl) 2006-06-13 2007-06-12 Zastosowanie inhibitora wazopeptydazy do leczenia tętniczego nadciśnienia płucnego

Country Status (16)

Country Link
US (1) US20100234393A1 (pl)
EP (1) EP2026796B1 (pl)
JP (1) JP5421099B2 (pl)
CA (1) CA2655019C (pl)
CY (1) CY1118473T1 (pl)
DK (1) DK2026796T3 (pl)
ES (1) ES2611311T3 (pl)
FR (1) FR2902009B1 (pl)
HR (1) HRP20170123T1 (pl)
HU (1) HUE030538T2 (pl)
LT (1) LT2026796T (pl)
PL (1) PL2026796T3 (pl)
PT (1) PT2026796T (pl)
RS (1) RS55663B1 (pl)
SI (1) SI2026796T1 (pl)
WO (1) WO2007144501A2 (pl)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083130A1 (en) * 2001-04-16 2002-10-24 Bristol-Myers Squibb Company Enantiomers of n-[[2'-[[(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-n,3,3-trimethylbutanamide
FR2837822B1 (fr) * 2002-03-29 2004-06-04 Bioprojet Soc Civ Formes polymorphes du fasidotril, leurs procedes de preparation et compositions pharmaceutiques les contenant
WO2003099194A2 (en) * 2002-05-23 2003-12-04 Pfizer Limited Pharmaceutical combination of pde5 inhibitors with ace inhibitors
US20040077624A1 (en) * 2002-05-23 2004-04-22 Pfizer Inc. Novel combination
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
CN1838958A (zh) * 2003-08-22 2006-09-27 贝林格尔·英格海姆药物公司 治疗慢性阻塞性肺病和肺动脉高血压的方法
TW200605867A (en) * 2004-03-17 2006-02-16 Novartis Ag Use of organic compounds
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
AU2005284798B2 (en) * 2004-09-15 2012-02-02 The President And Fellows Of Harvard College Reducing ER stress in the treatment of obesity and diabetes
WO2006126082A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors

Also Published As

Publication number Publication date
CY1118473T1 (el) 2017-07-12
CA2655019C (fr) 2014-11-25
DK2026796T3 (en) 2017-02-06
EP2026796A2 (fr) 2009-02-25
JP2009539949A (ja) 2009-11-19
EP2026796B1 (fr) 2016-11-09
HUE030538T2 (en) 2017-05-29
RS55663B1 (sr) 2017-06-30
ES2611311T3 (es) 2017-05-08
FR2902009B1 (fr) 2012-12-07
FR2902009A1 (fr) 2007-12-14
SI2026796T1 (sl) 2017-02-28
CA2655019A1 (fr) 2007-12-21
LT2026796T (lt) 2017-02-10
WO2007144501A3 (fr) 2008-02-21
US20100234393A1 (en) 2010-09-16
PT2026796T (pt) 2017-01-17
WO2007144501A2 (fr) 2007-12-21
HRP20170123T1 (hr) 2017-03-24
JP5421099B2 (ja) 2014-02-19

Similar Documents

Publication Publication Date Title
HK1153938A1 (en) Use of a cdk inhibitor for the treatment of glioma cdk
HK1218393A1 (zh) 用於治療肺高壓的複合物
HK1146484A1 (en) Thiazolidinedione analogues for the treatment of hypertension
SI2402317T1 (sl) DGAT inhibitor
EP2012766A4 (en) JAK2 INHIBITION AS TREATMENT OF LUNG ARTERY HIGH PRESSURE
EP2005957A4 (en) ACID SECRETION INHIBITOR
EP1986554A4 (en) FABRIC CLAMP
EP1764075A4 (en) HAMMER OF TISSUE FACTORING
EP2084139A4 (en) OXAZOLIDINIUM COMPOUNDS AND USE AS HYDRATINE HIBITORS
IL210922A0 (en) Treatment of pulmonary arterial hypertension
IL195331A0 (en) Hsp90 inhibitor
IL188850A0 (en) Cathepsin k inhibitors
HK1166795A1 (en) Use of a kinase inhibitor for the treatment of thymoma
SI2366393T1 (sl) Roflumilast za zdravljenje pljučne hipertenzije
EP2064178A4 (en) CATHEPSIN S INHIBITOR PRODRUGS
EP2038304A4 (en) BST2 INHIBITORS
IL177989A0 (en) Use of transcription factor inhibitor in the manufacture of a medicament
ZA200905761B (en) Transpiration inhibitor
IL193905A0 (en) Renin inhibitors for the treatment of hypertension
EP2177529A4 (en) NEW DE-SECRETASE INHIBITOR
LT2026796T (lt) Vazopeptidazės inhibitoriaus panaudojimas plaučių arterinės hipertenzijos gydymui
EP2134843A4 (en) RECOMBINANT KUNITZ HEMMER
GB0820885D0 (en) A composition for the treatment of hypertension
EP2076490A4 (en) INHIBITORS OF CATHEPSIN B
ZA200809814B (en) HSP90 Inhibitor